Olivier Mir
Mir, Olivier
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 313545338 (Personal)
Permalink: http://viaf.org/viaf/313545338
Preferred Forms
-
100 1 _
‡a
Mir, Olivier
-
100 1 _ ‡a Mir, Olivier
-
100 0 _
‡a
Olivier Mir
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Characterization of cellular 3D models of chordoma and evaluation of a radiosensitizing approach. |
|
| Cours de chimiothérapie antitumorale et traitement médical du cancer |
|
| Etude rétrospective des évènements neuro-vasculaires survenant sous traitements anti-VEGF |
|
| More on aprepitant for erlotinib-induced pruritus |
|
| Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma. |
|
| Objective response to sorafenib in advanced clear-cell sarcoma. |
|
| Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma. |
|
| [Oral drugs inhibiting the VEGF pathway] |
|
| Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment |
|
| Oxaliplatin in inoperable or metastatic bladder cancer |
|
| A painful cranial bulge |
|
| Patients âgés de plus [de] 75 ans et essais de phase I en cancérologie : expérience de l'Institut Gustave Roussy |
|
| Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study |
|
| PD-1 inhibition in bone sarcoma and soft-tissue sarcoma |
|
| Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works? |
|
| Pharmacokinetic interaction involving fenofibrate and everolimus |
|
| Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study |
|
| Pleural empyema secondary to amebic liver abscess |
|
| Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib |
|
| Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. |
|
| The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab |
|
| Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. |
|
| Predictive risks factors of cardiovascular toxicities during antiangiogenics. |
|
| [Pregnancy after breast cancer: an update] |
|
| Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms |
|
| Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial |
|
| Prognostic scoring systems for spinal metastases in the era of anti-VEGF therapies. |
|
| Pure red blood cell aplasia and isoniazid use |
|
| Raltegravir-induced DRESS syndrome |
|
| A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia |
|
| Reactivation of tuberculosis during temsirolimus therapy |
|
| Recurrent transaminitis induced by oral contraceptives during HIV infection |
|
| REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis |
|
| Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. |
|
| Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria |
|
| Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib |
|
| Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas) |
|
| Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial |
|
| Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients |
|
| Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors |
|
| Sarcoidosis lung nodules in colorectal cancer follow-up: sarcoidosis or not? |
|
| Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years |
|
| Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients |
|
| Saturable absorption of sorafenib in patients with solid tumors: a population model |
|
| The sentinel-node concept: a dramatic improvement in breast-cancer surgery |
|
| Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms |
|
| Sertraline-induced increase in VEGF brain levels and its activity in cryptococcal meningitis |
|
| Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients |
|
| A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. |
|
| Sorafenib exposure decreases over time in patients with hepatocellular carcinoma |
|
| Sorafenib in advanced melanoma: a critical role for pharmacokinetics? |
|
| Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications |
|
| Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo |
|
| Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. |
|
| Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C. |
|
| Surgery guided by mixed reality: presentation of a proof of concept |
|
| Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network |
|
| Tamponade with a thickened pericardium |
|
| Targeting angiogenesis in advanced soft tissue sarcoma: tivozanib-hype or me-too? |
|
| Targeting angiogenesis in chronic liver diseases with portal hypertension: anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib? |
|
| Taxane-induced skin toxicity and TNF-alpha |
|
| Taxanes during Pregnancy: Probably Safe, but Still to Be Optimized |
|
| Terrorist attacks in Paris: Surgical trauma experience in a referral center. |
|
| Tolérance du Sorafénib chez les sujets de plus de 70 ans : étude cas contrôle |
|
| Tolerance of sorafenib in patients over 70 years : case-control study. |
|
| Toward a new strategy in desmoid of the breast? |
|
| Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series |
|
| Treating Ulcerative Colitis During Pregnancy: Evidence of Materno-Fetal Transfer of Golimumab |
|
| Treatment of bevacizumab-induced hypertension by amlodipine. |
|
| Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir |
|
| Tropical pruritus |
|
| Tyrosine kinase inhibitors and pregnancy: A risk to the fetus? |
|
| Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. |
|
| Use of anticancer agents in gynecological oncology during pregnancy: a systematic review of maternal pharmacokinetics and transplacental transfer |
|
| Use of platinum derivatives during pregnancy |
|
| Using Anti-Cancer Agents during the Post-Partum Period: Not that Simple |
|
| Vaccination coverage among medical residents in Paris, France |
|
| Validation de modèles 3D de chordome et preuves de concept in vitro d'une stratégie radiosensibilisante |
|
| Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patients |
|
| Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis |
|
| Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model |
|
| VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption. |
|
| Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. |
|
| When Imaging Becomes Clinically Relevant: Multikinase Inhibitor-related Pancreatic Insufficiency and Pancreatic Atrophy |
|
